This paper examines the interpretation of placebo responses in clinical trials of systemic lupus erythematosus (SLE), using recent phase 3 data on obinutuzumab as a clinical example. While improvements observed in placebo groups are commonly attributed to nonspecific placebo effects or regression toward the mean, this analysis proposes an alternative interpretation grounded in dynamical systems thinking. Autoimmune diseases such as SLE may behave as dynamic biological systems characterized by fluctuations, instability, and transitions between states of higher and lower disease activity. From this perspective, part of the improvement observed in placebo groups may reflect intrinsic disease dynamics rather than purely methodological artifacts. The paper situates this interpretation within the framework of Dynamic Medicine and the Universal Resonance Model (URM). It is published as part of the Dynamic Medicine series, which explores how instability, timing, and system transitions shape disease behavior and clinical decision-making in complex biological systems.
Anita Domargård (Fri,) studied this question.